Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .
作者信息
D'Silva Kristin M, Serling-Boyd Naomi, Wallwork Rachel, Hsu Tiffany Y-T, Sparks Jeffrey A, Wallace Zachary Scott
机构信息
Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
出版信息
Ann Rheum Dis. 2022 Aug;81(8):e135. doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.
Abstract
摘要
相似文献
1
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .对马克斯所著《风湿性疾病患者的COVID-19：真正的死亡风险是什么？》的回应
Ann Rheum Dis. 2022 Aug;81(8):e135. doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.
2
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases.关于吉安弗兰切斯科所著《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在风湿性肌肉骨骼疾病患者中，疾病活动度而非糖皮质激素治疗，可能与新冠病毒肺炎的严重程度相关。
Ann Rheum Dis. 2022 Nov;81(11):e222. doi: 10.1136/annrheumdis-2020-218845. Epub 2020 Sep 7.
3
Rheumatic disease and COVID-19: epidemiology and outcomes.风湿性疾病与2019冠状病毒病：流行病学与结局
Nat Rev Rheumatol. 2021 Feb;17(2):71-72. doi: 10.1038/s41584-020-00562-2.
4
Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.关于“自身免疫性炎性风湿病患者中与 COVID-19 相关的住院风险因素”的通信
Ann Rheum Dis. 2023 Mar;82(3):e69. doi: 10.1136/annrheumdis-2020-219542. Epub 2020 Dec 18.
5
COVID-19 in Rheumatic Diseases: A Research Agenda.风湿性疾病中的新型冠状病毒肺炎：一项研究议程。
Arthritis Rheumatol. 2020 Oct;72(10):1596-1599. doi: 10.1002/art.41447. Epub 2020 Sep 22.
6
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.风湿性疾病患者感染新冠病毒后对严重急性呼吸综合征冠状病毒2的抗体反应。
Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.
7
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini .风湿性疾病患者中新型冠状病毒肺炎（COVID-19）的患病率：需要等待大型合作研究的结果。对Conticini所著《一大群接受生物和靶向合成抗风湿药物治疗的患者中的COVID-19肺炎》的回应
Ann Rheum Dis. 2021 Feb;80(2):e15. doi: 10.1136/annrheumdis-2020-217738. Epub 2020 May 15.
8
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani .对乔瓦尼所著《西班牙1037例接受生物制剂和JAK抑制剂治疗的风湿病患者中重症COVID-19的发病率》的回应
Ann Rheum Dis. 2022 Jul;81(7):e132. doi: 10.1136/annrheumdis-2020-218179. Epub 2020 Jun 25.
9
Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.38例接受改善病情抗风湿药治疗的风湿性疾病合并新型冠状病毒肺炎患者的特征与演变
Clin Rheumatol. 2021 Mar;40(3):1197-1199. doi: 10.1007/s10067-020-05510-9. Epub 2020 Nov 24.
10
Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.影响炎症性风湿性疾病中COVID-19病程的因素。
Clin Exp Rheumatol. 2023 Mar;41(3):758-759. doi: 10.55563/clinexprheumatol/3pcfrz. Epub 2022 Oct 13.
Zotero 插件